The evaluation of bone mineral density in long-term survival patients after allogeneic hematopoietic stem cell transplantation: cross sectional study by KSGCT

The evaluation of bone mineral density in long-term survival patients after allogeneic hematopoietic stem cell transplantation: cross sectional study by KSGCT - The evaluation of bone mineral density in long-term survival patients after allogeneic hematopoietic stem cell transplantation: KSGCT1701(Bone-Dx)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000030916

Enrollment

350

Registered

2018-04-01

Start date

2018-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hematological malignancies

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients'age >= 20 years at the time of investigation 2) Patients with disease-free surviving for 2 to 5 years after transplant 3) Not exclude patients with their history of skeletal related events 4) Patients who were informed and concented

Exclusion criteria

Exclusion criteria: 1) Patients who are otherwise classified as unfit by the attending physicians for this research. 2) Patients who underwent allogeneic and/or autologous transplantation more than once 3) Patients with multiple myeloma

Design outcomes

Primary

Measure	Time frame
The prevalence of osteoporosis( score =< -2.5)after allogeneic hematopoietic stem cell transplantation	—

Secondary

Measure	Time frame
1) The prevalence of osteopenia(-2.5 < T score =< -1.0)after allogeneic hematopoietic stem cell transplantation 2) The effect of patient characteristics on osteopenia or osteoporosis 3) The effect of menses discontinuation on osteopenia or osteoporosis 4) The effect of post-transplant complication such as GVHD (graft versus host disease) on osteopenia or osteoporosis 5) The effect of therapeutic intervention on osteopenia or osteoporosis 6) The effect of SRE (skeletal related events) on osteopenia or osteoporosis	—

Measure

Time frame

1) The prevalence of osteopenia(-2.5 < T score =< -1.0)after allogeneic hematopoietic stem cell transplantation 2) The effect of patient characteristics on osteopenia or osteoporosis 3) The effect of menses discontinuation on osteopenia or osteoporosis 4) The effect of post-transplant complication such as GVHD (graft versus host disease) on osteopenia or osteoporosis 5) The effect of therapeutic intervention on osteopenia or osteoporosis 6) The effect of SRE (skeletal related events) on osteopenia or osteoporosis

—

Countries

Japan

Contacts

Public ContactHIROTO ISHII

The Jikei university school of medicine Department of Clinical Oncology and Hematology

h-ishii@jikei.ac.jp03-3433-1111

Outcome results